The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase I/II trial of olaparib in combination with eribulin in patients with advanced or metastatic triple negative breast cancer (TNBC) previously treated with anthracyclines and taxanes: The analyses of efficacy and safety from phase II.
 
Masato Takahashi
No Relationships to Disclose
 
Kan Yonemori
No Relationships to Disclose
 
Harukaze Yamamoto
No Relationships to Disclose
 
Ken-ichi Watanabe
No Relationships to Disclose
 
Chikako Shimizu
No Relationships to Disclose
 
Hiroyuki Yasojima
No Relationships to Disclose
 
Norikazu Masuda
Honoraria - AstraZeneca; Chugai Pharma; Eisai; Kyowa Hakko Kirin
Research Funding - AstraZeneca (Inst); Chugai Pharma (Inst); Kyowa Hakko Kirin (Inst); Lilly (Inst); Novartis (Inst); Pfizer (Inst)
 
Seiki Takashima
No Relationships to Disclose
 
Kenjiro Aogi
Honoraria - AstraZeneca; Becton Dickinson; Chugai Pharma; Daiichi Sankyo; Eisai; Nihon Medi-Physics; Ono Pharmaceutical; Otsuka; Sanofi; Taiho Pharmaceutical
 
Nobuaki Matsubara
Speakers' Bureau - Sanofi
Research Funding - Bayer (Inst); Janssen-Ortho (Inst)
 
Yoichi Naito
Speakers' Bureau - AstraZeneca; Chugai Pharma; Eisai; Novartis; Taiho Pharmaceutical
 
Satoru Shimizu
No Relationships to Disclose
 
Naohito Yamamoto
Research Funding - AstraZeneca (Inst); Lilly (Inst); MSD (Inst); Pfizer (Inst)
 
Rikiya Nakamura
Research Funding - AstraZeneca Japan (Inst); Eisai (Inst); Nippon Kayaku (Inst)
 
Hirofumi Michimae
No Relationships to Disclose
 
Akinobu Hamada
Research Funding - AstraZeneca
 
Kenji Tamura
Research Funding - AstraZeneca; Eisai
 
Yasuhiro Fujiwara
Honoraria - AstraZeneca; Chugai Pharma; Eisai; Lilly; Yakult Honsha